scent1.png

Mapping the Coronavirus Fingerprint

 

Scentech-Medical completed two clinical trials at the Meir Medical Center and the IDF, in which breath samples were collected from patients and healthy subjects for the identification of the metabolic volatile organic compounds (VOCs) associated with the Covid-19 virus.

 

The trials were successful and the goal of the study was met – biomarkers associated with the virus, which can be detected using the company’s breath analysis technology, were found. Currently the company is carrying out a comprehensive validation experiment, which includes thousands of subjects at the Shamir Medical Center in Israel. As part of the test development, this trial is aimed at challenging the technology in order to make it operational as soon as possible. From preliminary examination of the results, it is apparent that the test will be 98% accurate in detecting coronavirus-positive patients.

Scentech-Medical completed two clinical trials at the Meir Medical Center and the IDF, in which breath samples were collected from patients and healthy subjects for the identification of the metabolic volatile organic compounds (VOCs) associated with the Covid-19 virus. The trials were successful and the goal of the study was met – biomarkers associated with the virus, which can be detected using the company’s breath analysis technology, were found. Currently the company is carrying out a comprehensive validation experiment, which includes thousands of subjects at the Shamir Medical Center in Israel. As part of the test development, this trial is aimed at challenging the technology in order to make it operational as soon as possible.

 

From preliminary examination of the results, it is apparent that the test will be over 90% accurate in detecting coronavirus-positive patients.​ In addition, the test will be able to detect patients at the asymptomatic stage, which will be accomplished by a straightforward, few minute-long breath test with on-the-spot results.​ It is also becoming apparent that beyond the detection of patients, the test will be able to detect antibodies and thus will be able to afford a similar solution to the serological test. Simultaneously, The company started preparing for device approval application to the FDA The company initiated an additional study using the same technology to test the efficacy of the vaccine in patients. In addition to the clinical trials, the company is in the process of merging with the shell company BioMed NextGen (TASE:NXGN) in Israel.

For a better tomorrow

Breath Test Development for Coronavirus Detection

Current Status

Our Product

VOX System

Rapid Breath Test for Coronavirus Detection

- Fast with on-the-spot results

- Accurate (over 90%)

- Non-invasive

- Able to detect patients in all stages of the disease, even asymptomatic patients.

 

- Designed for fast technological updates in light of mutations and new pathogens

System specifications: ​

 

Current system dimensions (first generation)

Length: 50 cm / Width: 60 cm

Future product dimensions (including a stand and wheels) 

Length:  120 cm / Width: 60 cm

 

Device Operation: One operator with no technical skills required.

 

Approximate Supply date (First Generation) Q1 – Q2 2021

​*  illustration 

VOX MODEL.png

​*  illustration 

Biological security

The coronavirus revealed that the world is not prepared against the threat of pathogens in the present or the future. We believe that from now on, in order for us to be safe against the coronavirus, its variants, and other pathogens, the world will have to protect itself with an additional protective layer of “Biological Security”. Which requires rapidly testing whether a person is infected with a certain virus or not in crowded passages such as airports, stadiums, shopping centers, and more. Our goal is to make such passages more secure using an advanced technology for the early, point-of-care detection of various pathogens.